Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

What this Trial Is About

This research aims to assess the long-term safety and effectiveness of pirtobrutinib in people who have previously been treated for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma. It is a Phase 4 study involving participants who completed an earlier study called LOXO-BTK-18001. The study invites these participants to continue their assigned treatment or follow-up in this extension study. Participants will continue receiving pirtobrutinib, which is taken orally, as they did in the original study. This study serves as an individual-study appendix under the master protocol J2N-MC-JZNY. There are no new treatment groups participants maintain the therapy they were assigned before. During the study, participants will be monitored for serious treatment-related side effects, including tracking any grade 3 or higher adverse events occurring from the first dose through 30 days after the last dose or until starting a new cancer therapy. Researchers will also observe overall survival up to 93 months from enrollment in the original study. Participants will have regular follow-up visits to assess their health and treatment safety over the long term.

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma